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Mature lymphocytes recirculate throughout the lymphatic system, a  process 
thought to be essential to the dissemination of immune responses. Lymphocytes 
in both human and murine species migrate from the bloodstream into lymphoid 
tissues  and  inflamed  sites  via  a  mechanism  requiring  specific  adherence  to 
specialized postcapillary high endothelial venules (HEV) (1). Circulating lympho- 
cytes adhere to HEV, and the lymphocytes then migrate through the endothelium 
into the surrounding tissue. In the mouse, we have shown (2) that a specific cell 
surface molecule on lymphocytes interacts with determinants on HEV of periph- 
eral  lymph nodes.  A  related but distinct set of surface receptor molecules are 
thought to be responsible for lymphocyte binding to HEV in gut-associated or 
Peyer's  patch  lymphoid  tissue.  Expression  of  functional  lymphocyte  surface 
receptors  for  endothelial  cells  is  thus  required  for  effective dissemination  of 
lymphoid cells and immune responses. 
The  discovery of interleukin-2  (IL-2),  or T  cell  growth factor,  has made it 
possible to maintain clones of functional murine and human T  cells in culture 
indefinitely (3, 4). This new technology gives rise to optimism for development 
of novel therapies based on the use of cloned effector cells to regulate or mediate 
in vivo immune responses in man. However, in vivo results using murine T  cell 
clones have been somewhat discouraging (5-7). Cloned murine T  cells have been 
shown to function in several in vivo systems, including transfer of experimental 
allergic encephalitis (8), mediation of delayed-type hypersensitivity (5), protection 
against  influenza virus  (9,  10),  aliogeneic tumor  cell  rejection  (11),  and  even 
protection against syngeneic lymphomas (12). However, these effects have usually 
required either infusion of very large numbers of cloned cells, direct presentation 
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of the cells to the tissue site where their function is to be assessed, or both (5- 
12). In one study (7,  11) of tumor cell rejection, allospecific cytotoxic T  lympho- 
cyte clones, even when preselected for the ability to eliminate aliogeneic tumor 
cells in vivo, were found to be 5-20  times less effective than equally cytotoxic 
Lyt-2  + cell populations from day 5 mixed leukocyte cultures. Although a variety 
of mechanisms,  such  as  active  suppression  of the  desired  immune  response, 
blocking  of antigenic  sites  with  antibodies,  and  more  complex  immune  cell 
interactions might explain the surprising inefficiency of murine T  cell clones in 
vivo,  a  simpler  explanation  is  possible:  the  common  observation  that  in  vivo 
responses are demonstrable after local but not systemic presentation of effector 
cells suggests a  deficiency in the capacity of cells maintained in vitro to localize 
effectively to in vivo tissue sites.  In support  of this, we reported  (13,  14)  that 
cloned murine T  cells lack functional or antigenically-defined surface receptors 
for HEV.  They are unable to bind HEV in vitro, lack the lymphocyte surface 
homing receptor for HEV defined by the monoclonal antibody MEL-14, and are 
unable to localize effectively in vivo to lymphoid tissues. 
This lack of functional homing capacity could be a major barrier to the use of 
functional T  cell clones for manipulation and analysis of immune responses in 
vivo. This problem could be especially important in the human system because 
of the potential of cloned effector T  cells for antitumor therapy, or for immune 
regulation in allergic or autoimmune diseases. We wished to determine whether 
cloned human T  cells, which are similar to their murine counterparts, also lack 
surface  receptors  for  HEV.  Expression  of functional HEV-binding ability was 
assayed in an  in  vitro model, recently adopted  from rodent systems, in  which 
mature lymphocytes bind to HEV in frozen sections of human lymph nodes or 
appendix  (15).  Human  T  cell  clones of both  cytotoxic/suppressor and  helper 
phenotypes were examined, and the results are reported here. 
Materials and Methods 
T Cell Clones.  Human T  cell clones were obtained from three independent sources. 
Several antigen-reactive and alloreactive T  cells of both cytotoxic/suppressor and helper 
phenotypes were tested. Alloreactive IL-2-producing (helper) T cell clones T4-31, CWN, 
C2-2,  and 22-27  (from J. Goronzy and C. Weyand) were grown in minimal amounts of 
recombinant IL-2 (CETUS,  Emeryville, CA).  Allospecific  cytotoxic T  cell clones AH7 
and F1 (from C. Clayberger and A. Krensky) (16) were grown in IL-2 obtained from the 
supernatant of phytohemagglutinin (PHA)-stimulated lymphocytes, and purified by am- 
monium sulfate precipitation (17). Purified protein derivative-specific helper T cell clones 
I15,  I5,  III3, and the suppressor clone III27  were also  grown in  IL-2 obtained from 
supernatant of PHA-stimulated lymphocytes. These cells have been described previously 
(18): I5 is from cell line 5; III3 is from cell line 13; III27 is from cell line 27; and I15 was 
not described, but was maintained in a similar fashion. 
In  Vitro Assay  of Lymphocyte Binding  to HEV.  This technique, recently described in 
humans (15), has been adapted from previous murine studies (19, 20). Briefly, lymphocytes 
in RPMI 1640 containing 25 mM Hepes, pH 7.3, and 5% fetal calf serum, were incubated 
with mild agitation for 30 min at 7°C on freshly cut frozen sections of human lymph 
nodes (normal or reactive cervical  or axillary nodes from biopsies) or appendix (from 
elective appendectomy during abdominal surgery). The sections were then fixed by placing 
slides in cold phosphate-buffered saline containing 1% glutaraldehyde, and nonadherent 
cells were gently rinsed off. Quantitative determination of the degree of binding of sample 
lymphocytes was made by using an internal standard population of fluorescein isothiocy- 
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analyses  have been  described  (15,  20).  The  relative  adherence  ratio (RAR)  is a  linear 
measure of the efficiency of cell binding to HEV (15), and is normalized so that the RAR 
of the reference population (ficoll-separated peripheral blood lymphocytes [PBL], included 
as an unlabeled sample population in each experiment)  is unity. Individual clones were 
tested  1-2 times, with similar results in duplicate experiments. 
Results 
As  shown  in  Table  I,  all  human  T  cell  clones  examined  bind  efficiently  to 
human peripheral  lymph node  HEV  in frozen  sections.  The  data are presented 
TABLE  I 
HEV Binding Ability of Human T Cell Clones 
Relative adherence ratios  t 
Cell  Type*  Phenotype  Specificity  Lymph node  Appendix 
HEV  HEV 
15  Th  Leu-3  ÷  PPD  1.1  4- 0.3  --! 
I15  Th  Leu-3*  PPD  0.7 4- 0.1  1.6 -4- 0.5 
1113  Th  Leu-3  ÷  PPD  0.8 --+ 0.2  -- 
T4-31  Th  --  DW14  3.9 4--- 0.8  -- 
CWN  Th  --  DR4  3.1  4- 0.6  -- 
C2-2  Th  --  DR4  1.5 +  0.3  2.8 4- 0.6 
22-27  Th  --  DWI4  2.7 4- 0.5  -- 
11127  Tc/s  Leu-2  ÷  PPD  1.4 -4- 0.4  -- 
AH7  Tc  Leu-2  ÷  HLA-A2  3.0 -4- 0.7  -- 
F1  Tc  Leu-3*  DR6  2.6 +  0.6  2.5 4- 0.5 
* Th, T  helper cell; Tc, cytotoxic T  cell; Ts, suppressor T  cell. 
* The relative adherence ratio is the calculated number of sample cells that would bind to 
HEV per PBL binding if an equal number of each were incubated on the sections under 
the same conditions. Values are reported +-- SE. 
! Not determined. 
FIGURE  1.  T  cells of the C2-2 clone binding to two HEV  in frozen section of appendix. The 
adherent cells are apparent as dark round circles above the plane of the section. The  HEV are 
vaguely outlined by their lightly stained basement membranes.  Thionine  stain, ×  250. 1078  NAVARRO  ET  AL.  BRIEF  DEFINITIVE  REPORT 
as RAR, relating the binding ability of the T  cell clones or lines to that of normal 
PBL (defined as unity). The results show that the T  cells tested adhere to lymph 
node HEV about the same as (RAR ~1),  or even better than  PBL (RAR >1). 
Also, three selected clones were assayed for binding to human appendix  HEV, 
as indicated in the last column. As in the case of peripheral node HEV adherence, 
binding of these clones to appendix HEV was comparable to or better than that 
of normal PBL (see also Fig.  1). 
Discussion 
The  results  show  that  human  T  cell  clones  are  able  to  specifically recog- 
nize and bind to HEV, a function that is essential for normal lymphocyte homing 
in  vivo. The capacity of human  T  cell clones to interact  with  HEV appears to 
be independent of their antigenic specificity, their major histocompatibility com- 
plex  subregion  restriction  or  Leu-3/Leu-2  phenotype, and  of their  functional 
(helper/suppressor/cytotoxic) properties.  Furthermore,  the T  cell clones exam- 
ined  were  obtained  from  three  independent  sources,  each  using  somewhat 
different methods of cell cultivation (see Materials and Methods). Thus it seems 
unlikely  that  expression  of functional  HEV-binding  capacity  is  influenced  by 
minor  differences  in  tissue  culture  protocols.  Taken  together,  the  uniform 
expression of HEV-binding ability by the  10 clones examined suggests that the 
expression of functional receptors for HEV may well be characteristic  of most, 
if not all IL-2-responsive human T  cells maintained in vitro. 
In murine  systems, the capacity of lymphocytes to bind to HEV in vitro has 
proven an accurate reflection of their ability to interact with HEV in vivo, and 
to migrate from the blood into lymphoid tissues (19-22). The ability of normal 
human  lymphocyte  populations  to  bind  in  vitro  to  HEV  also  parallels  their 
presumed migratory status in vivo (15). Thus, the binding of human T  cell clones 
to HEV strongly suggests that they may be able to migrate effectively in vivo, as 
well. However, expression of receptors for HEV, while certainly a  prerequisite 
for normal homing, may not in itself be sufficient for in vivo localization; clearly 
other requirements  must also be met for normal  recirculation  and  diapedesis. 
Critical studies of T  cell clone migration in primate model systems, as well as in 
human  systems using gamma  imaging  of cell  localization  to  lymph  nodes and 
other  tissues,  will  be  required  to  demonstrate  finally  the  in  vivo  migratory 
competence of human T  cell clones. 
These findings stand in marked contrast to previous studies (13,  14) showing 
that  murine  T  cell  clones lack  surface receptors  for  HEV,  and  are  unable  to 
localize  to  either  peripheral  or  gut-associated  lymphoid  tissues  in  vivo.  This 
functional  difference  between  human  and  murine  T  cell  clones  may  be  a 
reflection  of technical  differences  in  procedures  for  derivation  and  in  vitro 
propagation  of T  cells in  the  two species.  For example,  all  the  human  T  cell 
clones examined were derived from stimulated PBL, whereas murine clones are 
generally derived from stimulated spleen or lymph node cells. Experiments are 
in progress to rule out tissue source as a major determinant of receptor expres- 
sion. 
Another possibility is that there is a real difference between the two species in 
the regulation  of expression of homing receptors during T  cell differentiation, 
or in the stage of differentiation  at which human and murine activated T  cells 
express receptors for  IL-2.  Based on  studies  in  the  mouse, we have proposed NAVARRO ET  AL.  BRIEF  DEFINITIVE REPORT  1079 
(21)  that  most virgin  iymphocytes, before antigenic  stimulation,  express func- 
tional homing receptors for both lymph node and mucosal HEV; that antigenic 
stimulation leads to suppression of expression of both of these functional homing 
receptor classes; and  that  following a  period of local differentiation,  surviving 
cells  are  induced  or  selected  by  local  microenvironmental  factors  to  express 
homing receptors specific for the type of HEV associated with tissues similar to 
the site of antigenic stimulation (reviewed in 21). We have recently (S. Jalkanen, 
N.  Wu,  and  E.  C.  Butcher,  unpublished  observations)  identified  transformed 
human  B  lymphoblastoid cell  lines capable of discriminating  between mucosal 
(appendix) and peripheral  lymph node HEV,  thus confirming  the existence of 
organ-specific lymphocyte-endothelial cell recognition mechanisms in humans as 
in mice. In this study, three representative T  cell clones were tested and found 
to bind  well to appendix as well as lymph node HEV. This expression of dual 
recognition function, within the context of our model, may suggest either that 
human  IL-2-stimulated  T  cell clones represent a  somewhat earlier stage in the 
T  cell differentiation sequence, before loss of homing receptors, or possibly that 
the period of suppression of homing receptor expression observed (21) during 
murine T  cell proliferation is not a characteristic of proliferating human T  cells. 
Regardless  of  the  reason  for  the  species  differences  in  homing  receptor 
expression,  it  is  clear  that  the  murine  T  cell  clone  is an  imperfect  model  for 
defining the in vivo immunoregulatory or therapeutic potential of human T  cell 
clones.  These  findings  suggest  that  human  T  cell  clones may  well be able to 
traffic normally in vivo. This ability may allow human T  cell clones to perform 
more effectively, in  both  research  and  therapeutic  settings,  than  their  murine 
counterparts. 
Summary 
To function efficiently in vivo, lymphocytes must circulate from the blood into 
lymphoid  tissues  and  other  sites  of immune  reaction.  Herein,  we  show  that 
human cytotoxic and helper T  cell clones and lines, maintained in vitro with IL- 
2,  express  the  functional  capacity  to  recognize  and  bind  to  high  endothelial 
venules  (HEV),  a  capacity  essential  for  lymphocyte exit  from  the  blood,  and 
hence for normal  lymphocyte trafficking.  The expression of functional homing 
receptors  distinguishes  human  T  cell  clones  from  their  murine  counterparts, 
which  uniformly  lack receptors for  HEV and are  unable  to  migrate  normally 
from the blood in vivo. The results raise the possibility that human T  cell clones 
may be more effective in mediating in vivo immune responses than is suggested 
by murine models. 
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